33043-26-4

Basic information

• Product Name: N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine ethyl ester
• Synonyms: N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine ethyl ester
• CAS NO: 33043-26-4
• Molecular Weight: 465.547
• Mol File: 33043-26-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine ethyl ester(33043-26-4)
• EPA Substance Registry System: N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine ethyl ester(33043-26-4)

Safety Data

• Hazardous Substances Data: 33043-26-4(Hazardous Substances Data)

Upstream product

• 623-33-6 glycine ethyl ester hydrochloride 
• 2389-45-9 Boc-Lys(Z)-OH 
• 459-73-4 GlyOEt*HCl 
• 34404-36-9 Boc-Lys(Z)-OSu 

Downstream Products

• 57022-32-9 (S)-3-(4-aminobutyl)piperazine-2,5-dione 
• 37701-12-5 H-L-Lys(Z)-Gly-OEt*HCl 
• 53613-24-4 N-(N^α-tert-butoxycarbonyl-N^ε-carbobenzoxy-L-lysyl)glycine 
• 112471-88-2 Boc-(L-Lys(Z))2-Gly-(L-Phe)2-(Gly)3-OEt 
• 112471-89-3 Boc-(L-Lys(Z))2-Gly-(L-Phe)2-(Gly)3-OH 
• 68168-48-9 Boc-Lys(Z)-Lys(Z)-Gly-OEt 
• 112471-92-8 Cyclo-((L-Lys(Z))2-Gly-(L-Phe)2-(Gly)3) 
• 112471-91-7 H-(L-Lys(Z))2-Gly-(L-Phe)2-(Gly)3-OH*TFA 
• 112471-83-7 Boc-Lys(Z)-Lys(Z)-Gly-OH 
• 126333-42-4 N-α-(1-carbethoxy-3-phenylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>glycine 
• 126333-38-8 N-α-(1-carboxy-3-phenylpropyl)-N^ε-benzyloxycarbonyl-L-lysyl>glycine 
• 47376-71-6 N-(N^ε-carbobenzoxy-L-lysyl)-glycine 

Relevant articles and documents

Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "selectivity Pocket", Substrate-Binding Site, and NAD+-Binding Site

The NAD+-dependent deacetylase SIRT2 represents an attractive target for drug development. Here, we designed and synthesized drug-like SIRT2-selective inhibitors based on an analysis of the putative binding modes of recently reported SIRT2-selective inhibitors and evaluated their SIRT2-inhibitory activity. This led us to develop a more drug-like diketopiperazine structure as a "hydrogen bond (H-bond) hunter" to target the substrate-binding site of SIRT2. Thioamide 53, a conjugate of diketopiperazine and 2-anilinobenzamide which is expected to occupy the "selectivity pocket" of SIRT2, exhibited potent SIRT2-selective inhibition. Inhibition of SIRT2 by 53 was mediated by the formation of a 53-ADP-ribose conjugate, suggesting that 53 is a mechanism-based inhibitor targeting the "selectivity pocket", substrate-binding site, and NAD+-binding site. Furthermore, 53 showed potent antiproliferative activity toward breast cancer cells and promoted neurite outgrowth of Neuro-2a cells. These findings should pave the way for the discovery of novel therapeutic agents for cancer and neurological disorders.

Synthesis and angiotensin converting enzyme inhibitory activity of L-lysyl-N-substituted glycine derivatives

The synthesis and biological activity of novel L-lysyl-N-substituted glycine derivatives which exhibit in vitro and in vivo angiotensin converting enzyme (ACE) inhibition, are described. Particularly, N-[N(α)-(1-carboxy-3-phenylpropyl)-L-lysyl]-N-(4-pheny

Process for acylation with novel acylating agent

This invention relates to a novel acylation process which comprises using as the acylating agent an o-hydroxy-substituted aromatic oxime ester represented by the general formula (I) STR1 and mixing said acylating agent with an amine substance represented